Edition:
India

ARCA Biopharma Inc (ABIO.OQ)

ABIO.OQ on NASDAQ Stock Exchange Capital Market

0.56USD
16 Nov 2018
Change (% chg)

$0.02 (+3.70%)
Prev Close
$0.54
Open
$0.60
Day's High
$0.60
Day's Low
$0.54
Volume
24,332
Avg. Vol
138,297
52-wk High
$1.92
52-wk Low
$0.45

Latest Key Developments (Source: Significant Developments)

Arca Biopharma Announces Positive Outcome Of End-Of-Phase 2 Meeting With FDA On Gencaro Development For Atrial Fibrillation
Tuesday, 31 Jul 2018 

July 31 (Reuters) - ARCA Biopharma Inc ::ARCA BIOPHARMA ANNOUNCES POSITIVE OUTCOME OF END-OF-PHASE 2 MEETING WITH FDA ON GENCARO DEVELOPMENT FOR ATRIAL FIBRILLATION.ARCA BIOPHARMA INC - SINGLE PHASE 3 TRIAL MAY BE SUFFICIENT FOR APPROVAL OF ATRIAL FIBRILLATION INDICATION.ARCA BIOPHARMA INC - PHASE 3 CLINICAL TRIAL SPECIAL PROTOCOL ASSESSMENT SUBMISSION ANTICIPATED 3Q2018.ARCA BIOPHARMA - FDA SUGGESTED CO SUBMIT SPA APPLICATION, WHICH CO ANTICIPATES SUBMITTING IN Q3 2018.ARCA - EXPECTS INITIATING PHASE 3 CLINICAL TRIAL SUBJECT TO SECURING MORE FINANCING BY STRATEGIC PARTNERSHIP AND/OR ADDITIONAL SALES OF SECURITIES.  Full Article

Arca Biopharma Q1 Loss Per Share $0.20
Wednesday, 9 May 2018 

May 8 (Reuters) - ARCA Biopharma Inc ::ARCA BIOPHARMA ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $0.20.  Full Article

Arca Biopharma announces issuance of European patent on cardiovascular disease treatment methods
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Arca Biopharma Inc :Arca Biopharma announces issuance of European patent for treating cardiovascular diseases and conditions with a new chemical entity utilizing genetic targeting.Arca Biopharma- believes current cash, cash equivalents,marketable securities will be sufficient to fund its operations through end of Q2 of 2018​.  Full Article

ARCA Biopharma announces third quarter financial results
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Arca Biopharma Inc :ARCA Biopharma announces third quarter 2017 financial results and provides business update.Q3 loss per share $0.39.ARCA Biopharma Inc - anticipate reporting top-line data for Genetic-AF clinical trial​ late in Q1 of 2018.ARCA Biopharma Inc - ‍expects research and development expenses in 2017 to be higher than 2016​.  Full Article